BofA Trims Pfizer (PFE) PT as COVID-19 Sales Slide and Obesity Focus Shifts to Metsera [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
the firm's price target on Pfizer to $27 from $28 while keeping a Neutral rating on the shares. Pfizer's 2026 guidance revealed a steeper erosion of its COVID-19 franchise than previously projected, leading the firm to trim its near-term financial forecasts. The focus has now shifted to the company's obesity strategy; investors are awaiting trial results from the recently acquired Metsera assets to determine if they can successfully carve out a unique position in the high-growth weight-loss market. Additionally, on December 17, Pfizer and Astellas announced positive topline results from the Phase 3 EV-304 trial (KEYNOTE-B15). The study showed that the combination of PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) significantly improved both event-free survival and overall survival when used as a perioperative treatment (before and after surgery) for patients with muscle-invasive bladder cancer/MIBC. This trial specifically focused on patients eligible for cisplatin-based ch
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Flagship Pioneering and Repertoire® Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer [Yahoo! Finance]Yahoo! Finance
- Jim Cramer on Pfizer: “I'm Going to Say Just Weak Hold” [Yahoo! Finance]Yahoo! Finance
- BeOne Medicines names R&D chief Wang Lai as co-president to lead global expansion [Yahoo! Finance]Yahoo! Finance
- Better Buy in 2026: Pfizer or Merck? [Yahoo! Finance]Yahoo! Finance
- Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound [Seeking Alpha]Seeking Alpha
PFE
Earnings
- 11/4/25 - Beat
PFE
Sec Filings
- 12/17/25 - Form 4
- 12/16/25 - Form 8-K
- 12/2/25 - Form 4
- PFE's page on the SEC website